Canada \u00b7 Weight loss
Peptides for weight loss in Canada: what's authorized.
“Peptides for weight loss” in Canada mostly means GLP-1 medicines. Some are authorized prescription drugs; others are sold online as “research” products with no authorization. This page separates the two and links to what anonymous users report.
Authorized for weight management (prescription)
- Wegovy (semaglutide) and its generic, Sevmia.
- Zepbound (tirzepatide), authorized May 13, 2025.
- Saxenda (liraglutide), an older daily GLP-1.
Ozempic and Mounjaro are authorized for type 2 diabetes (Ozempic, Mounjaro). Check any DIN in the Drug Product Database. Unauthorized options people ask about, such as AOD-9604 and sermorelin for weight loss, have no Health Canada authorization for weight loss.
Not authorized in Canada
- Retatrutide — investigational, still in trials.
- AOD-9604, MOTS-c, cagrilintide — no Canadian authorization.
- Any “research use only” GLP-1 — see Health Canada's April 2026 advisory.
What semaglutide users report
- 37 published anonymous semaglutide confessions; 5 mention at least one side effect.
- 12 mention Ozempic, Wegovy or Rybelsus by name.
- Among confessions that state a weight change in pounds, the median reported is 50 lb. Self-reported, unverified.
Most-mentioned side effects (share of semaglutide confessions):
- Burping: 5.4% (2)
- Nausea: 5.4% (2)
- Vomiting: 5.4% (2)
- Anxiety or panic: 2.7% (1)
- Constipation: 2.7% (1)
Counts are phrase mentions in anonymous accounts, not diagnoses or clinical rates. Full breakdown and methodology: semaglutide side-effects report.
By province and city
Authorized weight-management drugs compared
Main trial averages, drug vs placebo. Not head-to-head.
| Drug | How often | Average weight change |
|---|---|---|
| Saxenda (liraglutide) | Daily | 8.0% vs 2.6%, 56 weeks |
| Wegovy (semaglutide) | Weekly | 14.9% vs 2.4%, 68 weeks |
| Zepbound (tirzepatide) | Weekly | About 15% to 21% vs 3%, 72 weeks |
None of the “research” peptides (retatrutide, AOD-9604, 5-amino-1MQ, tesofensine) is authorized. See AOD-9604 and retatrutide in Canada.
Last reviewed October 15, 2026against Health Canada's Drug Product Database and trial publications and Health Canada.
Related
- Community report pages
- Mazdutide vs retatrutide
- Eloralintide vs retatrutide
- What are peptides?
- Zepbound weight loss
- Rybelsus for weight loss
- AOD-9604 in Canada
- GLP-1 for weight loss
- Mazdutide
- Bimagrumab
- GLP-1 medications
- Peptides for weight loss (global)
- Best peptides for fat loss
- Tirzepatide side-effects report
- Ozempic alternatives in Canada
- Compounded GLP-1 in Canada
- GLP-1 medications in Canada
- Peptides in Canada hub
Frequently asked questions
- Which weight-loss drug works best in Canada?
- In their own trials, Zepbound and Wegovy produced more average weight loss than Saxenda; the right choice depends on health history and coverage.
- Which weight-loss peptides are approved in Canada?
- Health Canada has authorized peptide medicines for chronic weight management including Wegovy (semaglutide), Sevmia (generic semaglutide), Zepbound (tirzepatide) and Saxenda (liraglutide). All are prescription-only.
- Is retatrutide approved in Canada?
- No. Retatrutide is an investigational drug still in clinical trials and is not authorized in Canada. 'Research' retatrutide sold online is unauthorized.
- Are research peptides for weight loss legal in Canada?
- Health Canada says unauthorized peptides cannot be sold for human use and that 'research use only' labels give no exemption.
- Does this page recommend a weight-loss peptide or dose?
- No. We do not recommend products, sources or doses. A licensed Canadian prescriber can say whether any option suits you.
Sources
General information only — not medical, legal or regulatory advice. Peptide Confessions does not sell, source or recommend any product or vendor, and nothing here is dosing guidance. Speak with a licensed Canadian healthcare professional or pharmacist about any medication. Editorial process →